<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management and prognosis of alcoholic hepatitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management and prognosis of alcoholic hepatitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management and prognosis of alcoholic hepatitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott L Friedman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H234083145"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Excessive alcohol consumption is associated with a range of hepatic manifestations and takes a significant toll on human health throughout the world [<a href="#rid1">1-4</a>]. Moreover, alcoholic liver disease tends to be diagnosed at later stages than other liver diseases [<a href="#rid5">5</a>]. In the United States, the burden of alcoholic hepatitis is increasing [<a href="#rid6">6</a>]. Hepatic manifestations include alcoholic fatty liver disease (with or without steatohepatitis), alcoholic hepatitis, and cirrhosis. While asymptomatic steatohepatitis due to alcohol could be referred to as "alcoholic hepatitis," the term is typically used to describe the acute onset of symptomatic hepatitis. The amount of alcohol intake that puts an individual at risk for alcoholic hepatitis is not known, but the majority of patients have a history of heavy alcohol use (more than 100 g per day) for two or more decades  (<a class="graphic graphic_figure graphicRef56818" href="/z/d/graphic/56818.html" rel="external">figure 1</a>) [<a href="#rid7">7,8</a>].</p><p>This topic will review the prognosis and management of patients with alcoholic hepatitis. The pathogenesis of alcoholic liver disease, the clinical manifestations and diagnosis of alcoholic hepatitis, and the approach to patients with alcoholic fatty liver disease or alcoholic cirrhosis are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">"Pathogenesis of alcohol-associated liver disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86934.html" rel="external">"Alcoholic hepatitis: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3611.html" rel="external">"Management of alcohol-associated steatosis and alcohol-associated cirrhosis"</a>.)</p><p></p><p>Guidelines for the management of patients with alcoholic liver disease have been issued by the American Association for the Study of Liver Diseases, the American Gastroenterological Association, and the American College of Gastroenterology [<a href="#rid9">9,10</a>]. The discussion that follows is generally consistent with those guidelines.</p><p class="headingAnchor" id="H325299748"><span class="h1">DETERMINING DISEASE SEVERITY</span><span class="headingEndMark"> — </span>Several models have been proposed to determine the severity of a patient's alcoholic hepatitis [<a href="#rid11">11,12</a>]. The Maddrey discriminant function and the Model for End-stage Liver Disease (MELD) score are the most commonly used to help identify patients who are more likely to benefit from pharmacologic therapy. Other validated scores include the Glasgow alcoholic hepatitis score, the ABIC score (which includes age, serum bilirubin, international normalized ratio, and serum creatinine), and the Lille score (which is used to determine if a patient is responding to treatment) [<a href="#rid12">12-14</a>]. (See <a class="local">'Efficacy'</a> below.)</p><p class="headingAnchor" id="H251272027"><span class="h2">Maddrey discriminant function</span><span class="headingEndMark"> — </span>Disease severity and mortality risk in patients with alcoholic hepatitis may be estimated using the Maddrey discriminant function (DF, also known as the Maddrey score), which is calculated as follows (<a class="calc calc_professional" href="/z/d/html/15641.html" rel="external">calculator 1</a>) [<a href="#rid15">15,16</a>]:</p><p>For bilirubin in conventional units (mg/dL):</p><div class="formulaContainer"><div class="formula"><p>DF = (4.6 x [prothrombin time (sec) - control prothrombin time (sec)]) + (serum bilirubin)</p></div></div><p>For bilirubin in système international units (micromol/L):</p><div class="formulaContainer"><div class="formula"><p>DF = (4.6 x [prothrombin time (sec) - control prothrombin time (sec)]) + (serum bilirubin/17.1)</p></div></div><p>Patients with a DF value ≥32 have high short-term mortality and may benefit from treatment with glucocorticoids, whereas those with lower scores have low short-term mortality and do not appear to benefit from glucocorticoids. (See <a class="local">'Prognosis'</a> below and <a class="local">'Efficacy'</a> below.)</p><p class="headingAnchor" id="H251272037"><span class="h2">MELD score</span><span class="headingEndMark"> — </span>The MELD score is a statistical model developed to predict survival in patients with cirrhosis that has also been used to predict mortality in patients hospitalized for alcoholic hepatitis [<a href="#rid17">17-19</a>]. The score ranges from 6 to 40 and is based on the serum bilirubin, creatinine, and international normalized ratio (<a class="calc calc_professional" href="/z/d/html/15636.html" rel="external">calculator 2</a> and <a class="calc calc_professional" href="/z/d/html/16498.html" rel="external">calculator 3</a>). (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p>In one report, a MELD score &gt;11 performed as well as the DF in predicting 30-day mortality [<a href="#rid17">17</a>]. The sensitivity and specificity of MELD for predicting 30-day mortality were 86 and 81 percent, respectively, and for the DF were 86 and 48 percent, respectively. In a second study, a MELD score of ≥21 had a sensitivity of 75 percent and a specificity of 75 percent for predicting 90-day mortality [<a href="#rid18">18</a>]. </p><p>In addition, an increase in the MELD score of ≥2 points in the first week of hospitalization may independently predict in-hospital mortality [<a href="#rid19">19</a>].</p><p>A proposed scoring system that combines alterations in hepatic gene expression with MELD score (gene signature-MELD) has been used to predict survival at 180 days for patients with severe alcoholic hepatitis [<a href="#rid20">20</a>]. The score requires a liver biopsy, which limits its routine clinical use. </p><p class="headingAnchor" id="H251272046"><span class="h2">Glasgow alcoholic hepatitis score</span><span class="headingEndMark"> — </span>The Glasgow alcoholic hepatitis (GAH) score predicts mortality in alcoholic hepatitis and is based on a multivariable model that includes age, serum bilirubin, blood urea nitrogen, prothrombin time, and peripheral white blood cell count (<a class="calc calc_professional" href="/z/d/html/15645.html" rel="external">calculator 4</a>) [<a href="#rid21">21,22</a>]. An initial validation study with 195 patients with alcoholic hepatitis found that a GAH score ≥9 had lower sensitivity but higher specificity for predicting 28-day mortality than a DF of ≥32 (81 versus 96 percent and 61 versus 27 percent, respectively) [<a href="#rid22">22</a>]. Similar results were seen when it was compared with the MELD score (using a MELD cutoff of 11).</p><p>A subsequent validation study with 225 patients with a DF ≥32 found that patients with a GAH score ≥9 who received glucocorticoids had higher survival rates compared with those who did not receive glucocorticoids (78 versus 52 percent survival at 28 days and 59 versus 38 percent survival at 84 days) [<a href="#rid21">21</a>]. However, no survival benefit with glucocorticoids was seen among the patients with a GAH score &lt;9. </p><p class="headingAnchor" id="H247120663"><span class="h2">Hepatic histology score</span><span class="headingEndMark"> — </span>A histologic scoring system has been introduced that may assist in stratifying severity and predicting 90-day mortality [<a href="#rid23">23</a>]. Key parameters that correlate with outcome include the degree of fibrosis and neutrophilic infiltration, type of bilirubinostasis, and presence of megamitochondria. It was developed using predictors of 90-day mortality derived from a study of 121 patients with alcoholic hepatitis. Scores range from 0 to 9. A score of 0 to 3 was associated with a low risk of mortality within 90 days (3 percent), a score of 4 to 5 was associated with a moderate risk of mortality (19 percent), and a score of 6 to 9 was associated with a high risk of mortality (51 percent). The hepatic histology score requires a biopsy, which is not routinely performed in patients with alcoholic hepatitis. (See  <a class="medical medical_review" href="/z/d/html/3635.html" rel="external">"Histologic scoring systems for chronic liver disease"</a>.)</p><p class="headingAnchor" id="H234081667"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H234081674"><span class="h2">Treatment considerations for all patients</span><span class="headingEndMark"> — </span>The management of alcoholic hepatitis includes treatment for alcohol withdrawal and providing hemodynamic and nutritional support. Patients may develop complications such as infections or conditions related to cirrhosis, which also require treatment. Most patients with alcoholic hepatitis require inpatient hospitalization, and some will also need critical care support (eg, those with respiratory failure or sepsis). (See <a class="local">'Complications of cirrhosis'</a> below and <a class="local">'Critically ill patients'</a> below.)</p><p>Consultation with a gastroenterologist or hepatologist is recommended to assist with management, especially for patients who fail to respond to pharmacologic treatment. (See <a class="local">'Glucocorticoids'</a> below and <a class="local">'Pentoxifylline'</a> below.) </p><p>Patients should remain hospitalized if there is evidence of active infection, renal failure, severe coagulopathy and/or liver failure, alcohol withdrawal, delirium tremens, or other complications. Once these have been excluded and the patient is hemodynamically stable (with or without ongoing glucocorticoid usage), discharge can be considered, provided that there is sufficient social support and patient insight to ensure good compliance with medications, abstinence from alcohol, and close medical follow-up. The approach to treating alcohol use disorder is presented separately. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and <a class="local">'Alcohol abstinence and withdrawal'</a> below.) </p><p class="headingAnchor" id="H251271990"><span class="h3">Alcohol abstinence and withdrawal</span><span class="headingEndMark"> — </span>All patients with alcoholic hepatitis should abstain from alcohol. Pharmacologic therapy may aid with abstinence, and this is discussed separately [<a href="#rid24">24-27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Alcohol abstinence'</a>.)</p><p>Since many patients have a long history of excessive alcohol use, they are at risk for alcohol withdrawal. Therefore, the prevention and treatment of alcohol withdrawal is an important part of a patient's management. A systematic review of interventions for alcohol abstinence in patients with chronic liver disease found that when combined with comprehensive medical care, psychosocial interventions such as cognitive behavioral therapy, motivational enhancement therapy, can induce abstinence and reduce the risk of relapse [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes", section on 'Prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes", section on 'Management'</a>.)</p><p class="headingAnchor" id="H251272000"><span class="h3">Hydration</span><span class="headingEndMark"> — </span>Poor oral intake prior to presentation may result in dehydration, so many patients require fluid resuscitation. We prefer to use albumin rather than crystalloid for patients with prerenal azotemia and underlying cirrhosis, and the management of prerenal disease and/or hepatorenal syndrome is discussed separately [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.) </p><p>Overhydration should be avoided since it may increase the degree of ascites, lower the plasma sodium concentration, and occasionally precipitate gastrointestinal hemorrhage from varices [<a href="#rid30">30</a>]. Thus, patients without prerenal azotemia should not be routinely given maintenance fluids, particularly if they are able to tolerate oral fluids. (See  <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p class="headingAnchor" id="H3026274138"><span class="h3">Nutrition</span><span class="headingEndMark"> — </span>Most patients with severe alcoholic hepatitis are malnourished and require nutritional support. In a Veterans Administration Cooperative Study that included 284 patients with alcoholic hepatitis who underwent a complete nutritional assessment, signs of tissue wasting and severe protein-calorie malnutrition (eg, hypoalbuminemia, edema) were evident in almost all patients [<a href="#rid31">31</a>]. Indices of malnutrition correlated closely with the clinical severity of liver disease.</p><p>The goal of nutritional support is to provide adequate calories and protein, in addition to vitamin (eg, <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">thiamine</a>, folate, and pyridoxine) and mineral (eg, phosphate, magnesium) repletion [<a href="#rid32">32</a>]. Of note, <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> is usually given to patients with a prolonged prothrombin time, even though this regimen is often ineffective because the coagulopathy is more a reflection of underlying liver failure than vitamin K deficiency. Oral vitamin K is not well absorbed; a parenteral route of administration is preferred for these patients. Vitamin replacement and management of hemostatic abnormalities in patients with liver disease are discussed in more detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14614.html" rel="external">"Nutritional status in patients with sustained heavy alcohol use", section on 'Supplementation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2624.html" rel="external">"Overview of vitamin K", section on 'Vitamin K deficiency'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p>Protein intake is well tolerated and should not be restricted in patients with alcoholic hepatitis. In patients who develop encephalopathy associated with protein feeding, the use of branched-chain amino acids may be helpful. (See  <a class="medical medical_review" href="/z/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment", section on 'Nutritional support'</a> and  <a class="medical medical_review" href="/z/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment", section on 'Branched-chain amino acids'</a>.)</p><p>If the patient cannot maintain adequate oral intake, enteral tube feeding is generally preferred over intravenous nutrition. In our experience, patients with severe alcoholic hepatitis have very poor oral intake without regular assistance from nursing staff, relatives, or friends. If calorie counts demonstrate inadequate oral intake, a postpyloric feeding tube can greatly improve calorie intake. If the patient pulls the tube out unintentionally, a bridle can be used to keep the tube in place. </p><p>Efficacy of nutrition therapy in alcoholic hepatitis has been evaluated in multiple clinical trials [<a href="#rid33">33-37</a>], and most studies have demonstrated improvement in liver function and histology but without a consistent reduction in mortality. Nutrition therapy has been studied in combination with or as an alternative to glucocorticoids [<a href="#rid38">38-40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A pilot, open-label study suggested that combining nutritional therapy with glucocorticoids might allow for a shorter course of glucocorticoids, but further studies are needed [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One randomized trial assigned 71 patients with severe alcoholic hepatitis to <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or enteral tube feeding for 28 days and then followed the patients for one year [<a href="#rid40">40</a>]. Early mortality during treatment was similar in patients who received prednisolone and in those who received enteral tube feeding (25 versus 31 percent, respectively), although deaths occurred later in those who received prednisolone (median 23 versus 7 days). Among the 51 patients who were discharged from the hospital, mortality over the long term was higher in the prednisolone group (37 versus 8 percent).</p><p></p><p class="headingAnchor" id="H374281155"><span class="h3">Complications of cirrhosis</span><span class="headingEndMark"> — </span>Patients with alcoholic hepatitis may also have underlying cirrhosis. These patients may present with complications of cirrhosis and portal hypertension such as hepatic encephalopathy, ascites, or variceal bleeding. The management of complications of cirrhosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.) </p><p>For patients with typical symptoms of hepatic encephalopathy, a trial of <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a> and/or <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> should be given, with further evaluation (including head imaging) to exclude other diagnoses if the patient does not improve. The clinical manifestations, diagnosis, and treatment of hepatic encephalopathy is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1237.html" rel="external">"Hepatic encephalopathy in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H2769180945"><span class="h2">Critically ill patients</span><span class="headingEndMark"> — </span>Admission to an intensive care unit should be considered in patients who are unstable or combative. In addition, patients who are inebriated or have hepatic encephalopathy may require airway protection. Critical care support also includes sepsis surveillance and stress ulcer prophylaxis. Ulcer prophylaxis can be discontinued upon discharge from the hospital unless there is another indication for continuation. </p><p class="headingAnchor" id="H916518099"><span class="h3">Infection surveillance</span><span class="headingEndMark"> — </span>Patients with evidence of possible infection (eg, fever, worsening mental status, hemodynamic instability) should have blood and urine cultures obtained. Sputum cultures should be obtained if the patient has a productive cough or is intubated, and cerebrospinal fluid examined and cultured in those patients with fever and neurologic signs or symptoms suggestive of central nervous system infection rather than typical hepatic encephalopathy (eg, headache with fever, nuchal rigidity, or lateralizing neurologic deficits). In addition, if present, ascitic fluid should be obtained for culture, cell count with differential, total protein, and albumin level. Cultures are required because it is often impossible to distinguish between the fever of hepatitis and that of infection based solely on clinical criteria. (See  <a class="medical medical_review" href="/z/d/html/86934.html" rel="external">"Alcoholic hepatitis: Clinical manifestations and diagnosis", section on 'Signs and symptoms'</a>.)</p><p>While not yet translated into changes in clinical management, there is growing recognition that the microbiome (both bacteria and fungi) are altered in patients with alcoholic hepatitis and may contribute to disease severity because of toxin production by either bacteria or fungi [<a href="#rid41">41-45</a>].</p><p class="headingAnchor" id="H3137439176"><span class="h3">Renal failure and acute kidney injury</span><span class="headingEndMark"> — </span>Critically ill patients with alcoholic hepatitis may develop renal failure, which is associated with increased mortality [<a href="#rid46">46,47</a>]. The goal is to identify and treat conditions (eg, sepsis) that may lead to acute kidney injury or renal failure. Hepatorenal syndrome is a potential etiology in patients with a rising creatinine despite fluid resuscitation and discontinuation of diuretics. The approach to the diagnosis and treatment of hepatorenal syndrome is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">"Hepatorenal syndrome"</a>.)</p><p class="headingAnchor" id="H1507703001"><span class="h3">Ulcer prophylaxis</span><span class="headingEndMark"> — </span>We give patients prophylaxis against gastric mucosal bleeding with a proton pump inhibitor, histamine-2 receptor antagonist, or <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a>, particularly if the patient is in an intensive care unit, is receiving glucocorticoids, or has occult blood detected in the stool. Choosing an agent for ulcer prophylaxis in the critically ill patient is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">"Stress ulcers in the intensive care unit: Diagnosis, management, and prevention", section on 'Prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/2544.html" rel="external">"Evaluation of occult gastrointestinal bleeding", section on 'Testing for occult blood'</a>.)</p><p class="headingAnchor" id="H293805366"><span class="h2">Mild to moderate alcoholic hepatitis</span><span class="headingEndMark"> — </span>Abstinence from alcohol is the mainstay of treatment in patients with mild to moderate alcoholic hepatitis (Maddrey discriminant function [DF] &lt;32) (<a class="calc calc_professional" href="/z/d/html/15641.html" rel="external">calculator 1</a>). In addition, general supportive care (eg, nutritional support and hydration) should be provided, but pharmacologic treatment with glucocorticoids is not recommended in patients with mild to moderate alcoholic hepatitis [<a href="#rid10">10</a>]. While glucocorticoids may provide a short-term survival benefit in alcoholic hepatitis, patients with mild to moderate disease have a relatively favorable prognosis, and therefore, potential benefits do not outweigh potential harm. <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> has only been studied in patients with severe alcoholic hepatitis. (See <a class="local">'Treatment considerations for all patients'</a> above and <a class="local">'Efficacy'</a> below and <a class="local">'Mortality'</a> below.)</p><p class="headingAnchor" id="H234081688"><span class="h2">Severe alcoholic hepatitis</span></p><p class="headingAnchor" id="H477029444"><span class="h3">Glucocorticoids</span></p><p class="headingAnchor" id="H1186715842"><span class="h4">Indications and contraindications</span><span class="headingEndMark"> — </span>In addition to general supportive care, we suggest treatment with glucocorticoids (40 mg per day) for patients with severe alcoholic hepatitis (DF ≥32 (<a class="calc calc_professional" href="/z/d/html/15641.html" rel="external">calculator 1</a>)) [<a href="#rid48">48</a>]. However, not all authorities agree with this recommendation, instead favoring <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> in certain populations in light of inconclusive evidence of glucocorticoid efficacy [<a href="#rid49">49</a>]. <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">Prednisolone</a> has traditionally been given, provided there are no contraindications to its use (eg, active bacterial or fungal infection or chronic hepatitis C virus or hepatitis B virus infection) [<a href="#rid10">10</a>]. </p><p>Glucocorticoids must be used cautiously, particularly in patients who are unlikely to return for follow-up after discharge from the hospital. In the absence of a clinician guiding treatment, these patients are at risk for continuing glucocorticoids long term (with all of the associated side effects). In such patients, the benefits of glucocorticoids must be weighed against the risk of the patient's failing to receive follow-up medical care. </p><p>Careful monitoring for evidence of infection, gastrointestinal bleeding, or glucose intolerance is essential while the patient is on glucocorticoid therapy. In one report, infection developed in 24 percent of 57 patients who received glucocorticoids and was more likely to develop in those who did not respond to glucocorticoids (43 versus 11 percent) [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H916903616"><span class="h4">Administration</span><span class="headingEndMark"> — </span>We treat selected patients with severe alcoholic hepatitis with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 40 mg per day. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is an alternative if prednisolone is unavailable [<a href="#rid48">48</a>]. Prednisolone is preferred over prednisone because the latter requires conversion to prednisolone (the active form) in the liver, a process that may be impaired in alcoholic hepatitis. <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">Methylprednisolone</a> 32 mg daily by intravenous route is used for patients who cannot take oral medications and if intravenous prednisolone is not available (ie, North America).</p><p>For patients who respond to treatment, we continue <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> for 28 days [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2858454293"><span class="h4">Response and early termination of treatment</span><span class="headingEndMark"> — </span>For patients who receive glucocorticoids, the duration of treatment is 28 days. However, we stop therapy in patients who fail to show signs of improvement after one week (ie, those who fail to have improvement in their bilirubin or DF) (<a class="calc calc_professional" href="/z/d/html/15641.html" rel="external">calculator 1</a>).</p><p>The Lille score is another method to determine if patients with alcoholic hepatitis are responding to glucocorticoid therapy. We do not use the Lille score when deciding whether to continue treatment, but since it incorporates a bilirubin decrease in response to steroids, it may also be used. The score was derived using a cohort of 295 patients with alcoholic hepatitis who were treated with glucocorticoids [<a href="#rid13">13</a>]. It combines six variables: age, renal insufficiency (Cr &gt;1.3 or creatinine clearance &lt;40 mL/minute), albumin, prothrombin time, bilirubin, and evolution of bilirubin at day 7 (bilirubin at day 7 – bilirubin at day 0). Online <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.lillemodel.com%2Fscore.asp%3Fscore%3Dlillept&amp;token=e1d%2Bz4orcYrW9NXUjEGAV7%2BCbli44eYacMn2233d15ex0Ns1DlYo9Bi%2FOYn15LyA6dzG5YUIBOiiT3s6BeGcXA%3D%3D&amp;TOPIC_ID=87052" target="_blank">calculators</a> are available for the calculating the Lille score. A score &gt;0.45 suggests that a patient is not responding to glucocorticoid therapy. </p><p>In a validation cohort of 118 patients, the 40 percent of patients who had a Lille score &gt;0.45 had a higher mortality at six months compared to those with a lower score (75 versus 15 percent) [<a href="#rid13">13</a>]. In addition, the Lille score performed better than the DF, Child-Pugh score, or Glasgow alcoholic hepatitis score in predicting survival at six months. In another study using individual patient data from five clinical trials, a Lille score ≥0.56 predicted no response to glucocorticoid therapy as measured by hazard ratio for 28-day mortality [<a href="#rid51">51</a>]. </p><p class="headingAnchor" id="H234081695"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of glucocorticoids in alcoholic hepatitis has been evaluated in multiple randomized trials and meta-analyses, with mixed results [<a href="#rid15">15,49,51-67</a>]. Mortality rates after one to six months among patients treated with glucocorticoids in these trials ranged from 15 to 63 percent. Some of the variability may be related to differences in disease severity among the trials. Adding to the uncertainty is that many studies did not provide good documentation on complications of glucocorticoids in this setting [<a href="#rid49">49</a>]. (See <a class="local">'Determining disease severity'</a> above.)</p><p>In a 2017 meta-analysis of 15 randomized trials including 1861 patients with alcoholic hepatitis, mortality risk was not significantly different for patients treated with glucocorticoids compared with those given placebo (28 versus 30 percent; RR 0.90, 95% CI 0.70-1.15) [<a href="#rid49">49</a>]. When the analysis was restricted to trials with patients with severe alcoholic hepatitis (DF ≥32 or hepatic encephalopathy), there was also no significant difference in mortality risk (RR 0.92, 95% CI 0.73-1.16). The investigators assessed the quality of the evidence as low due to high risk of bias; they also noted that adverse events and complications of treatment were not clearly reported in many trials. </p><p>These results are somewhat at odds with conclusions derived from an earlier (2011) meta-analysis that examined patient-level data from five randomized trials (221 patients with severe alcoholic hepatitis) and found that glucocorticoid treatment was associated with lower 28-day mortality rates compared with placebo (20 versus 34 percent) [<a href="#rid51">51</a>]. In a subsequently published randomized trial (STOPAH), which included 1103 patients with severe alcoholic hepatitis, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> showed a trend toward improving 28-day survival (odds ratio 0.72, 95% CI 0.52-1.01) [<a href="#rid52">52</a>]. A 2015 meta-analysis that included the STOPAH trial among the eight included trials found that 28-day mortality was reduced in patients who received glucocorticoids (RR= 0.54; 95% CI 0.33- 0.84) [<a href="#rid53">53</a>]. Data on long-term outcomes is more limited, but do not show a benefit for glucocorticoid treatment [<a href="#rid49">49,51-53</a>].</p><p class="headingAnchor" id="H234081702"><span class="h3">Pentoxifylline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> is an alternative to glucocorticoids for patients who have contraindications to glucocorticoids or who are at risk for sepsis or for failing to follow up after discharge (and thus may not be tapered off of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, which could result in serious adverse effects). In addition, some authorities favor pentoxifylline because it may provide more benefit for certain subgroups of patients (eg, those with renal failure) compared with glucocorticoids [<a href="#rid10">10</a>].</p><p><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> is given as 400 mg three times per day (400 mg once per day in patients with a creatinine clearance &lt;30 mL per minute). A bilirubin less than 5 mg/dL may be an appropriate time to stop therapy. Pentoxifylline should be stopped earlier in patients who develop dyspepsia that limits oral intake. Pentoxifylline inhibits tumor necrosis factor (TNF) synthesis, which is increased in patients with alcoholic hepatitis. </p><p><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> has a good safety profile; however, the use of pentoxifylline in the management of alcoholic hepatitis remains controversial because the data are inconsistent [<a href="#rid52">52,53,68,69</a>]. Several studies and meta-analyses failed to show a benefit with regard to mortality [<a href="#rid68">68,70-74</a>], while other studies and meta-analyses have suggested that pentoxifylline may prevent hepatorenal syndrome and/or decrease mortality [<a href="#rid53">53,71,75,76</a>].</p><p>Short- and medium-term mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>The STOPAH trial did not show a mortality benefit with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, but it had several important limitations [<a href="#rid52">52</a>]. The STOPAH trial included 1103 patients with a DF ≥32 who were randomly assigned to receive placebo, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, pentoxifylline, or both prednisolone and pentoxifylline. The odds ratio for mortality for patients receiving pentoxifylline (with or without prednisolone) was 1.07 (95% CI 0.77-1.49). However, it is important to note that the mortality rate seen in patients who did not receive prednisolone or pentoxifylline (17 percent) was significantly lower than seen in the placebo arms from other trials (approximately 25 to 45 percent at one month) [<a href="#rid15">15,51,75,77</a>]. </p><p></p><p class="bulletIndent1">This lower-than-expected mortality rate in patients who received placebo suggests that the patients included in the trial may not be representative of patients with severe alcoholic hepatitis in general; it could also reflect generally improved care of patients in the trial. Ways in which the patients may not have been representative include the possible inclusion of patients with diagnoses other than alcoholic hepatitis and the exclusion of patients with renal failure, active gastrointestinal bleeding, untreated sepsis, or the need for inotropic support if their condition did not stabilize within the first seven days. </p><p></p><p class="bulletIndent1">Importantly, the exclusion of patients with renal failure may have biased the results against <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> because much of the benefit with pentoxifylline appears to be related to preventing or reversing hepatorenal syndrome. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of four trials including 350 patients showed a trend toward a lower risk of mortality with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> compared with placebo (RR 0.74, 95% CI 0.46-1.18) [<a href="#rid53">53</a>]. A meta-analysis of four trials including 459 patients showed that the combination of a glucocorticoid and pentoxifylline was not superior to treatment with a glucocorticoid alone with regard to short- or medium-term mortality (RR 0.94, 95% CI 0.69-1.30).</p><p></p><p>Acute kidney injury (AKI):</p><p class="bulletIndent1"><span class="glyph">●</span>In the STOPAH trial, AKI occurred in nine of 546 patients (2 percent) who received <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> compared with 14 of 546 patients (3 percent) who did not [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of four trials including 347 patients, there was a trend toward decreasing the risk of AKI with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> compared with placebo (RR 0.45, 95% CI 0.17-1.16) [<a href="#rid53">53</a>]. When glucocorticoids combined with pentoxifylline were compared with glucocorticoids alone, there was a trend toward decreasing the risk of AKI with dual therapy (RR 0.24, 95% CI 0.24-1.15).</p><p></p><p>Among patients who fail to respond to glucocorticoid therapy, substituting <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> for <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> does not appear to be effective [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H59685760"><span class="h3">Discontinue nonselective beta blockers</span><span class="headingEndMark"> — </span>In patients with severe alcoholic hepatitis, the use of nonselective beta blockers has been associated with an increased risk of acute kidney injury (AKI) [<a href="#rid79">79</a>]. As a result, we discontinue beta blockers in patients with severe alcoholic hepatitis. In a study of 139 patients with severe alcoholic hepatitis, the cumulative incidence of AKI at nearly six months was higher in patients who received nonselective beta blockers compared with those who did not (90 versus 50 percent) [<a href="#rid79">79</a>].</p><p>In addition, beta blockers should not be started in patients with alcoholic hepatitis; thus, we suggest deferring screening endoscopy for varices until the patient has fully recovered. </p><p class="headingAnchor" id="H164407366"><span class="h3">Possibly effective treatments</span><span class="headingEndMark"> — </span>Several other medical therapies have been investigated for the treatment of severe alcoholic hepatitis, but whether they will have a role in the routine treatment of alcoholic hepatitis is unclear [<a href="#rid12">12,80,81</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a><strong> (NAC) </strong>–<strong> </strong>The combination of NAC, an antioxidant, with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> has been studied for the treatment of severe alcoholic hepatitis, but it may not be more effective than prednisolone alone. A randomized trial with 174 patients compared treatment with either four weeks of prednisolone or four weeks of prednisolone plus NAC given on days one through five [<a href="#rid82">82</a>]. There was no difference in six-month mortality (the primary endpoint) between those who received prednisolone and those who received prednisolone plus NAC (38 versus 27 percent). While mortality was higher among those treated with prednisolone alone at one month (24 versus 8 percent), the difference was no longer statistically significant at three months (34 versus 22 percent). However, given the trend toward increased survival in those treated with NAC, additional study is warranted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulocyte colony-stimulating factor (GCSF)</strong> – The theory behind using GCSF in patients with severe alcoholic hepatitis is that GCSF may mobilize bone marrow-derived stem cells and promote hepatic regeneration. In a randomized, nonblinded trial with 46 patients with severe alcoholic hepatitis, patients were assigned to receive standard medical care (<a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> with other supportive measures) plus GCSF (5 mcg/kg subcutaneously every 12 hours for five days) or standard medical care alone [<a href="#rid83">83</a>]. Survival at 90 days was higher in the patients who received GCSF than in those who did not (78 versus 30 percent). However, it should be noted that the survival rate for patients in the standard care alone arm was lower than what has been seen in other studies of pentoxifylline (with variable lengths of follow-up). Survival rates with pentoxifylline in other trials have ranged from 71 percent at 28 days to 75 percent at six months. </p><p></p><p class="headingAnchor" id="H234081709"><span class="h3">Ineffective treatments</span><span class="headingEndMark"> — </span>Ineffective treatments for alcoholic hepatitis that have been studied include anti-TNF antibodies and anabolic steroids.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-TNF antibodies </strong>– TNF-alpha is believed to play a role in the pathogenesis of alcoholic hepatitis, but trials using anti-TNF antibodies have had disappointing results. (See  <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">"Pathogenesis of alcohol-associated liver disease", section on 'Injurious cytokines'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">Etanercept</a> is a soluble TNF receptor: FC fusion protein that binds to and neutralizes soluble TNF. While initial observational studies of etanercept showed a possible benefit [<a href="#rid84">84</a>], a randomized controlled trial in patients with moderate to severe alcoholic hepatitis did not [<a href="#rid85">85</a>]. Compared with placebo, etanercept was associated with significantly higher mortality (mainly due to infection) after six months (58 versus 23 percent).</p><p></p><p class="bulletIndent1">Another anti-TNF antibody, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, has also been studied for the treatment of severe alcoholic hepatitis. Infliximab is a chimeric mouse-human anti-TNF monoclonal antibody that was associated with clinical improvement in open-label trials [<a href="#rid86">86,87</a>]. Infliximab was then studied in a randomized trial with 36 patients with severe alcoholic hepatitis [<a href="#rid88">88</a>]. The patients were assigned to infliximab (10 mg/kg at days 0, 14, and 28) or placebo. All patients also received <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (40 mg daily) for 28 days. The study was stopped early due to higher mortality at two months in the infliximab group (39 versus 18 percent), though the increase was not statistically significant. Infections were more common in the infliximab group (72 versus 17 percent, p = 0.002), with severe infections accounting for half of the deaths. The study was criticized because high doses of infliximab were used (10 mg/kg at days 0, 14, and 28), though the open-label studies that used lower doses also found high infection rates [<a href="#rid86">86,87</a>]. In addition, it is not known if the increased infection rate in the infliximab group was due to the infliximab alone or due to the combined effects of infliximab plus prednisolone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anabolic steroids </strong>–<strong> </strong>Androgens have been used in an attempt to improve nutritional status in patients with alcoholic hepatitis, but they are likely ineffective. Promising results were seen in a subset of patents from a multicenter Veterans Administration trial of <a class="drug drug_general" data-topicid="10181" href="/z/d/drug information/10181.html" rel="external">oxandrolone</a> that included 263 patients with moderate or severe alcoholic hepatitis [<a href="#rid57">57</a>]. While there was no benefit in short-term survival, there was some benefit in long-term survival among patients who survived for at least one month. However, no benefit could be demonstrated in a systematic review of five randomized trials of patients with alcoholic hepatitis and/or cirrhosis [<a href="#rid89">89</a>]. </p><p></p><p class="headingAnchor" id="H234081716"><span class="h3">Liver transplantation</span><span class="headingEndMark"> — </span>Patients with severe alcoholic hepatitis who fail to respond to treatment with glucocorticoids or <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> may require liver transplantation [<a href="#rid90">90,91</a>]. However, because alcoholic hepatitis implies recent alcohol abuse, such patients usually do not receive transplantations, and the issue presents an ethical dilemma to providers and patients [<a href="#rid92">92</a>] (see  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease"</a>). Nonetheless, an increasing number of centers are performing liver transplantation in highly selected patients with severe alcoholic hepatitis [<a href="#rid93">93</a>]. A model study reinforces the extension of survival for patients with alcoholic hepatitis who receive a liver transplantation [<a href="#rid94">94</a>].</p><p>Moreover, harmful drinking after transplantation is associated with severe recurrent disease [<a href="#rid95">95</a>]. Nonetheless, in two small trials of highly selected patients, liver transplantation was associated with six-month survival rates of 77 [<a href="#rid96">96</a>] and 100 percent [<a href="#rid97">97</a>]. In one of these studies, the six month alcohol relapse rate in patients receiving early liver transplant was similar to that in a control group who underwent transplant after six months of abstinence (24 versus 29 percent) [<a href="#rid97">97</a>]. Greater emphasis on substance abuse training before and after transplant may also reduce the alcohol relapse rate among those who are transplanted [<a href="#rid98">98</a>].</p><p class="headingAnchor" id="H2432778161"><span class="h3">Refractory patients</span><span class="headingEndMark"> — </span>Patients with severe alcoholic hepatitis who do not respond to supportive care, nutritional therapy, and pharmacologic therapy, who are not candidates for liver transplantation, and who have multiple (≥four) organ failures, may be considered for palliative therapy [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/86296.html" rel="external">"Palliative care for patients with end-stage liver disease"</a>.)</p><p class="headingAnchor" id="H2860850645"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2552188885"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Mortality rates among patients who do not receive pharmacologic therapy (eg, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>) for alcoholic hepatitis are variable. In patients with severe alcoholic hepatitis (typically defined by a Maddrey discriminant function ≥32 (<a class="calc calc_professional" href="/z/d/html/15641.html" rel="external">calculator 1</a>)), short-term mortality rates are high (approximately 25 to 45 percent at one month) [<a href="#rid15">15,51,75,77</a>], whereas patients with mild to moderate alcoholic hepatitis have lower short-term mortality rates (&lt;10 percent at one to three months) [<a href="#rid36">36,99</a>]. In one study, the primary causes of death were hepatic failure (55 percent), gastrointestinal bleeding (21 percent), and sepsis (7 percent) [<a href="#rid77">77</a>]. (See <a class="local">'Determining disease severity'</a> above.)</p><p>Multiple risk factors for increased mortality in patients with alcoholic hepatitis have been identified and some have been incorporated into prognostic models. Long-term outcomes are also poor if patients have presented with acute decompensation, with 50 percent five-year mortality [<a href="#rid100">100</a>]. (See <a class="local">'Determining disease severity'</a> above.)</p><p>Risk factors for increased mortality include [<a href="#rid12">12,23,46,100-106</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Older age</p><p class="bulletIndent1"><span class="glyph">●</span>Acute kidney injury</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated bilirubin level</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated international normalized ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytosis</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol consumption &gt;120 g per day</p><p class="bulletIndent1"><span class="glyph">●</span>Infection (sepsis, spontaneous bacterial peritonitis, pneumonia, urinary tract infection, aspergillosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic encephalopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Upper gastrointestinal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Bilirubin to gamma glutamyl transferase ratio &gt;1</p><p class="bulletIndent1"><span class="glyph">●</span>High hepatic histology score (see <a class="local">'Hepatic histology score'</a> above) </p><p class="bulletIndent1"><span class="glyph">●</span>Systemic inflammatory response syndrome (see  <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Definitions'</a>)</p><p></p><p class="headingAnchor" id="H234081730"><span class="h2">Course after recovery</span><span class="headingEndMark"> — </span>An important determinant of outcome among patients with alcoholic hepatitis is whether the patients continue to drink alcohol. In a series that included 87 patients with alcoholic hepatitis who survived their index hospitalization, the overall estimated five-year survival rate was 32 percent [<a href="#rid107">107</a>]. However, among those who abstained from alcohol, the estimated survival rate was 75 percent, whereas for relapsed and continued drinkers it was 27 and 21 percent, respectively. </p><p>However, even if patients abstain from alcohol, they remain at risk for progressive liver disease [<a href="#rid108">108,109</a>]. In one series of 61 patients, 18 percent of those who initially had alcoholic hepatitis without cirrhosis progressed to cirrhosis despite alcohol abstinence [<a href="#rid108">108</a>]. In addition, histologic features of alcoholic hepatitis persisted for up to 14 months after discontinuing alcohol, suggesting that resolution of inflammation is slow. Thus, even patients who abstain from alcohol require ongoing evaluation for the development of cirrhosis (see  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>). Enrollment in an alcohol rehabilitation program within 30 days of discharge can improve outcomes by reducing readmission and death in patients with alcoholic hepatitis [<a href="#rid110">110</a>].</p><p>It has been our observation that a marked elevation in serum bilirubin with slow normalization of aminotransferases that remain in an alcoholic pattern (aspartate aminotransferase &gt;alanine aminotransferase) may be seen for many months following an episode of alcoholic hepatitis, even in patients who abstain from alcohol, perhaps reflecting the persistent histologic changes. Thus, the presence of persistently abnormal serum aminotransferases does not necessarily indicate that a patient is continuing to drink alcohol. </p><p class="headingAnchor" id="H906875190"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116328.html" rel="external">"Society guideline links: Alcohol-associated liver disease"</a>.)</p><p class="headingAnchor" id="H234083008"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the severity</strong> – Several prognostic models have been proposed to determine the severity of a patient's alcoholic hepatitis. The Maddrey discriminant function (DF) (<a class="calc calc_professional" href="/z/d/html/15641.html" rel="external">calculator 1</a>) and Model for End-stage Liver Disease are the most commonly used to identify patients with severe alcoholic hepatitis (DF ≥32) who are more likely to benefit from pharmacologic therapy (<a class="calc calc_professional" href="/z/d/html/15636.html" rel="external">calculator 2</a> and <a class="calc calc_professional" href="/z/d/html/16498.html" rel="external">calculator 3</a>). The Lille score has also been well validated. (See <a class="local">'Determining disease severity'</a> above.)</p><p></p><p class="bulletIndent1">For patients with severe alcoholic hepatitis, short-term mortality rates are high (approximately 25 to 35 percent at one month), whereas patients with mild to moderate alcoholic hepatitis have low short-term mortality rates (&lt;10 percent at one to three months). (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management of all patients</strong> – Patients with alcoholic hepatitis require general supportive care, including (see <a class="local">'Treatment considerations for all patients'</a> above and <a class="local">'Discontinue nonselective beta blockers'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol abstinence </p><p class="bulletIndent2"><span class="glyph">•</span>Prevention and treatment of alcohol withdrawal</p><p class="bulletIndent2"><span class="glyph">•</span>Fluid management</p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional support</p><p class="bulletIndent2"><span class="glyph">•</span>Infection surveillance</p><p class="bulletIndent2"><span class="glyph">•</span>Prophylaxis against gastric mucosal bleeding</p><p></p><p class="bulletIndent1">In addition, we suggest that nonselective beta blockers are discontinued in patients with severe alcoholic hepatitis (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with mild to moderate alcoholic hepatitis</strong> – The mainstay of treatment for patients with mild to moderate alcoholic hepatitis is abstinence from alcohol and supportive care. In patients with mild to moderate alcoholic hepatitis (DF &lt;32), we recommend <strong>against</strong> pharmacologic therapy with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Prednisolone does not appear to be beneficial in such patients. In addition, we suggest <strong>against</strong> pharmacologic therapy with <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Pentoxifylline has not been studied in this population, and its efficacy in patients with more severe alcoholic hepatitis has not been established. (See <a class="local">'Mild to moderate alcoholic hepatitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with severe alcoholic hepatitis (DF ≥32)</strong> – In patients with severe alcoholic hepatitis (DF ≥32), we suggest treatment with glucocorticoids (40 mg per day) along with supportive care (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Administration'</a> above). If there are no signs of improvement (ie, decreasing bilirubin or DF) after one week of therapy, we stop glucocorticoid treatment; otherwise we treat for 28 days. (See <a class="local">'Severe alcoholic hepatitis'</a> above.)</p><p></p><p class="bulletIndent1">However, not all authorities agree with this recommendation, instead favoring <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> in certain populations. This includes patients with contraindications to glucocorticoids (see <a class="local">'Indications and contraindications'</a> above) as well as those whose social circumstances place them at risk for poor continuity of care. </p><p></p><p class="bulletIndent1">As an example, patients who are homeless and given a prescription for glucocorticoids may not receive proper follow-up to ensure that the glucocorticoids are discontinued after 28 days. By contrast, the safety profile of <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> (400 mg three times per day [or once daily in patients with a creatinine clearance &lt;30 mL/minute]) is relatively favorable in such settings. A bilirubin less than 5 mg/dL may be an appropriate time to stop pentoxifylline. Pentoxifylline should be stopped earlier in patients who develop dyspepsia that limits oral intake. (See <a class="local">'Pentoxifylline'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who fail medical therapy</strong> – Patients who fail to respond to medical therapy may require liver transplantation before a six-month waiting period. However, such patients must be very carefully selected to ensure a minimal risk of alcohol relapse after transplant. (See  <a class="medical medical_review" href="/z/d/html/3608.html" rel="external">"Liver transplantation for alcohol-associated liver disease", section on 'Patients with severe alcohol-associated hepatitis (AH)'</a> and <a class="local">'Liver transplantation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013; 59:160.</a></li><li><a class="nounderline abstract_t">Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58:593.</a></li><li><a class="nounderline abstract_t">Moon AM, Yang JY, Barritt AS 4th, et al. Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century. Am J Gastroenterol 2020; 115:79.</a></li><li><a class="nounderline abstract_t">Bennett K, Enki DG, Thursz M, et al. Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. Aliment Pharmacol Ther 2019; 50:249.</a></li><li><a class="nounderline abstract_t">Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clin Gastroenterol Hepatol 2019; 17:2320.</a></li><li><a class="nounderline abstract_t">Jinjuvadia R, Liangpunsakul S, Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium. Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States. J Clin Gastroenterol 2015; 49:506.</a></li><li><a class="nounderline abstract_t">Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17:564.</a></li><li><a class="nounderline abstract_t">Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25:108.</a></li><li><a class="nounderline abstract_t">Mitchell MC, Friedman LS, McClain CJ. Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol 2017; 15:5.</a></li><li><a class="nounderline abstract_t">Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol 2018; 113:175.</a></li><li><a class="nounderline abstract_t">Lafferty H, Stanley AJ, Forrest EH. The management of alcoholic hepatitis: a prospective comparison of scoring systems. Aliment Pharmacol Ther 2013; 38:603.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="abcecad8c7c4cdcdc2c8ceebcecad8c7c4cdcdc2c8ce85cede">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69:154.</a></li><li><a class="nounderline abstract_t">Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45:1348.</a></li><li><a class="nounderline abstract_t">Dominguez M, Rincón D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103:2747.</a></li><li><a class="nounderline abstract_t">Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113:299.</a></li><li><a class="nounderline abstract_t">Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75:193.</a></li><li><a class="nounderline abstract_t">Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2:2.</a></li><li><a class="nounderline abstract_t">Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41:353.</a></li><li><a class="nounderline abstract_t">Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42:700.</a></li><li><a class="nounderline abstract_t">Trépo E, Goossens N, Fujiwara N, et al. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology 2018; 154:965.</a></li><li><a class="nounderline abstract_t">Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56:1743.</a></li><li><a class="nounderline abstract_t">Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54:1174.</a></li><li><a class="nounderline abstract_t">Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146:1231.</a></li><li><a class="nounderline abstract_t">Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370:1915.</a></li><li><a class="nounderline abstract_t">Enserink M. Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy. Science 2011; 332:653.</a></li><li><a class="nounderline abstract_t">Avanesyan A, Runyon BA. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcoholic hepatitis in a real-life clinical setting. Hepatology 2010; 52:1104A.</a></li><li><a class="nounderline abstract_t">Heydtmann M, MacDonald B, Lewsey J, et al. The GABA-B agonist baclofen imporves alcohol consumption, psychometrics and may have an effect on hospital admission rates in patients ith alcoholic liver disease. Hepatology 2012; 56:1091A.</a></li><li><a class="nounderline abstract_t">Khan A, Tansel A, White DL, et al. Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. Clin Gastroenterol Hepatol 2016; 14:191.</a></li><li><a class="nounderline abstract_t">Wong F, Nadim MK, Kellum JA, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60:702.</a></li><li><a class="nounderline abstract_t">Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.</a></li><li><a class="nounderline abstract_t">Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76:211.</a></li><li><a class="nounderline abstract_t">Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360:2758.</a></li><li><a class="nounderline abstract_t">Bonkovsky HL, Fiellin DA, Smith GS, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991; 86:1200.</a></li><li><a class="nounderline abstract_t">Mezey E, Caballería J, Mitchell MC, et al. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991; 14:1090.</a></li><li><a class="nounderline abstract_t">Achord JL. A prospective randomized clinical trial of peripheral amino acid-glucose supplementation in acute alcoholic hepatitis. Am J Gastroenterol 1987; 82:871.</a></li><li><a class="nounderline abstract_t">Simon D, Galambos JT. A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis. J Hepatol 1988; 7:200.</a></li><li><a class="nounderline abstract_t">Diehl AM, Boitnott JK, Herlong HF, et al. Effect of parenteral amino acid supplementation in alcoholic hepatitis. Hepatology 1985; 5:57.</a></li><li><a class="nounderline abstract_t">Alvarez MA, Cabré E, Lorenzo-Zúñiga V, et al. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004; 16:1375.</a></li><li><a class="nounderline abstract_t">Moreno C, Deltenre P, Senterre C, et al. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology 2016; 150:903.</a></li><li><a class="nounderline abstract_t">Cabré E, Rodríguez-Iglesias P, Caballería J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32:36.</a></li><li><a class="nounderline abstract_t">Smirnova E, Puri P, Muthiah MD, et al. Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity. Hepatology 2020; 72:271.</a></li><li><a class="nounderline abstract_t">Dong TS, Katzka W, Lagishetty V, et al. A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD. Sci Rep 2020; 10:2771.</a></li><li><a class="nounderline abstract_t">Lang S, Duan Y, Liu J, et al. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology 2020; 71:522.</a></li><li><a class="nounderline abstract_t">Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol 2020; 72:391.</a></li><li><a class="nounderline abstract_t">Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575:505.</a></li><li><a class="nounderline abstract_t">Altamirano J, Fagundes C, Dominguez M, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2012; 10:65.</a></li><li><a class="nounderline abstract_t">Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51:1637.</a></li><li><a class="nounderline abstract_t">Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-Chronic Liver Failure Clinical Guidelines. Am J Gastroenterol 2022; 117:225.</a></li><li><a class="nounderline abstract_t">Pavlov CS, Varganova DL, Casazza G, et al. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev 2017; 11:CD001511.</a></li><li><a class="nounderline abstract_t">Louvet A, Wartel F, Castel H, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137:541.</a></li><li><a class="nounderline abstract_t">Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60:255.</a></li><li><a class="nounderline abstract_t">Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372:1619.</a></li><li><a class="nounderline abstract_t">Singh S, Murad MH, Chandar AK, et al. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. Gastroenterology 2015; 149:958.</a></li><li><a class="nounderline abstract_t">Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47:277.</a></li><li><a class="nounderline abstract_t">Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36:480.</a></li><li><a class="nounderline abstract_t">Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23:75.</a></li><li><a class="nounderline abstract_t">Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311:1464.</a></li><li><a class="nounderline abstract_t">Depew W, Boyer T, Omata M, et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78:524.</a></li><li><a class="nounderline abstract_t">Shumaker JB, Resnick RH, Galambos JT, et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69:443.</a></li><li><a class="nounderline abstract_t">Blitzer BL, Mutchnick MG, Joshi PH, et al. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22:477.</a></li><li><a class="nounderline abstract_t">Campra JL, Hamlin EM Jr, Kirshbaum RJ, et al. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973; 79:625.</a></li><li><a class="nounderline abstract_t">Porter HP, Simon FR, Pope CE, et al. Corticosteroid therapy in severe alcoholic hepatitis. N Engl J Med 1971; 284:1250.</a></li><li><a class="nounderline abstract_t">Mathurin P, Louvet A, Dharancy S. Treatment of severe forms of alcoholic hepatitis: where are we going? J Gastroenterol Hepatol 2008; 23 Suppl 1:S60.</a></li><li><a class="nounderline abstract_t">Reynolds TB, Benhamou JP, Blake J, et al. Treatment of acute alcoholic hepatitis. Gastroenterol Int 1989; 2:308.</a></li><li><a class="nounderline abstract_t">Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110:1847.</a></li><li><a class="nounderline abstract_t">Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326:507.</a></li><li><a class="nounderline abstract_t">Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110:685.</a></li><li><a class="nounderline abstract_t">Park SH, Kim DJ, Kim YS, et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol 2014; 61:792.</a></li><li><a class="nounderline abstract_t">Singal AK, Shah VH. Therapeutic Strategies for the Treatment of Alcoholic Hepatitis. Semin Liver Dis 2016; 36:56.</a></li><li><a class="nounderline abstract_t">Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; :CD007339.</a></li><li><a class="nounderline abstract_t">Parker R, Armstrong MJ, Corbett C, et al. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37:845.</a></li><li><a class="nounderline abstract_t">Mathurin P, Louvet A, Duhamel A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310:1033.</a></li><li><a class="nounderline abstract_t">Sidhu SS, Goyal O, Singla P, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57:1664.</a></li><li><a class="nounderline abstract_t">Halegoua-De Marzio DL, Fenkel JM. Treatment of severe alcoholic hepatitis with corticosteroids and pentoxifylline. JAMA 2013; 310:1029.</a></li><li><a class="nounderline abstract_t">Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637.</a></li><li><a class="nounderline abstract_t">De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15:1613.</a></li><li><a class="nounderline abstract_t">Yu CH, Xu CF, Ye H, et al. Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials. World J Gastroenterol 2010; 16:2435.</a></li><li><a class="nounderline abstract_t">Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48:465.</a></li><li><a class="nounderline abstract_t">Sersté T, Njimi H, Degré D, et al. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int 2015; 35:1974.</a></li><li><a class="nounderline abstract_t">Torok NJ. Update on Alcoholic Hepatitis. Biomolecules 2015; 5:2978.</a></li><li><a class="nounderline abstract_t">Rachakonda V, Bataller R, Duarte-Rojo A. Recent advances in alcoholic hepatitis. F1000Res 2020; 9.</a></li><li><a class="nounderline abstract_t">Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365:1781.</a></li><li><a class="nounderline abstract_t">Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014; 109:1417.</a></li><li><a class="nounderline abstract_t">Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99:255.</a></li><li><a class="nounderline abstract_t">Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135:1953.</a></li><li><a class="nounderline abstract_t">Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38:419.</a></li><li><a class="nounderline abstract_t">Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009; 50:584.</a></li><li><a class="nounderline abstract_t">Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39:1390.</a></li><li><a class="nounderline abstract_t">Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2006; :CD003045.</a></li><li><a class="nounderline abstract_t">Lucey MR. Liver transplantation for alcoholic liver disease. Nat Rev Gastroenterol Hepatol 2014; 11:300.</a></li><li><a class="nounderline abstract_t">Weeks SR, Sun Z, McCaul ME, et al. Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series. J Am Coll Surg 2018; 226:549.</a></li><li><a class="nounderline abstract_t">Donckier V, Lucidi V, Gustot T, Moreno C. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60:866.</a></li><li><a class="nounderline abstract_t">Im GY, Kim-Schluger L, Shenoy A, et al. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience. Am J Transplant 2016; 16:841.</a></li><li><a class="nounderline abstract_t">Lee BP, Samur S, Dalgic OO, et al. Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. Gastroenterology 2019; 157:472.</a></li><li><a class="nounderline abstract_t">Rice JP, Eickhoff J, Agni R, et al. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl 2013; 19:1377.</a></li><li><a class="nounderline abstract_t">Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365:1790.</a></li><li><a class="nounderline abstract_t">Lee BP, Chen PH, Haugen C, et al. Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. Ann Surg 2017; 265:20.</a></li><li><a class="nounderline abstract_t">Rodrigue JR, Hanto DW, Curry MP. Substance abuse treatment and its association with relapse to alcohol use after liver transplantation. Liver Transpl 2013; 19:1387.</a></li><li><a class="nounderline abstract_t">Mezey E, Potter JJ, Rennie-Tankersley L, et al. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40:40.</a></li><li><a class="nounderline abstract_t">Degré D, Stauber RE, Englebert G, et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function &lt;32. J Hepatol 2020; 72:636.</a></li><li><a class="nounderline abstract_t">Altamirano J, Higuera-de laTijera F, Duarte-Rojo A, et al. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. Am J Gastroenterol 2011; 106:1472.</a></li><li><a class="nounderline abstract_t">Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011; 45:714.</a></li><li><a class="nounderline abstract_t">Ali S, Hussain S, Hair M, Shah AA. Comparison of Maddrey Discriminant Function, Child-Pugh Score and Glasgow Alcoholic Hepatitis Score in predicting 28-day mortality on admission in patients with acute hepatitis. Ir J Med Sci 2013; 182:63.</a></li><li><a class="nounderline abstract_t">Poynard T, Zourabichvili O, Hilpert G, et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984; 4:324.</a></li><li><a class="nounderline abstract_t">Gustot T, Maillart E, Bocci M, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol 2014; 60:267.</a></li><li><a class="nounderline abstract_t">Michelena J, Altamirano J, Abraldes JG, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015; 62:762.</a></li><li><a class="nounderline abstract_t">Potts JR, Goubet S, Heneghan MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 38:584.</a></li><li><a class="nounderline abstract_t">Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 1972; 63:1026.</a></li><li><a class="nounderline abstract_t">Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol 1987; 4:364.</a></li><li><a class="nounderline abstract_t">Peeraphatdit TB, Kamath PS, Karpyak VM, et al. Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol 2020; 18:477.</a></li></ol></div><div id="topicVersionRevision">Topic 87052 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23511777" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global burden of alcoholic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419824" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The burden of liver disease in Europe: a review of available epidemiological data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31688021" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31231848" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30708110" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198164" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8477961" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8985274" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Excess weight risk factor for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979049" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336434" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACG Clinical Guideline: Alcoholic Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23879668" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The management of alcoholic hepatitis: a prospective comparison of scoring systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29628280" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : EASL Clinical Practice Guidelines: Management of alcohol-related liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17518367" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721242" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A new scoring system for prognostic stratification of patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2142869" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/352788" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Corticosteroid therapy of alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11835693" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660383" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : MELD accurately predicts mortality in patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15826720" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29158192" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17627961" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009691" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24440674" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A histologic scoring system for prognosis of patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068515" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21551041" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Utilization of baclofen in maintenance of alcohol abstinence in patients with alcoholic hepatitis in a real-life clinical setting</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The GABA-B agonist baclofen imporves alcohol consumption, psychometrics and may have an effect on hospital admission rates in patients ith alcoholic liver disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26256464" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325171" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281973" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Transfusion strategies for acute upper gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6421159" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553649" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1909085" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1959859" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307390" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A prospective randomized clinical trial of peripheral amino acid-glucose supplementation in acute alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3142949" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917968" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of parenteral amino acid supplementation in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618848" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764182" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10869286" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32056227" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32066758" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31228214" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31606552" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723265" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21946124" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16927139" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35006099" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acute-on-Chronic Liver Failure Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096421" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Glucocorticosteroids for people with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445945" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940288" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25901427" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prednisolone or pentoxifylline for alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26091937" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532088" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943418" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7035299" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6390194" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6985881" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/356593" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/326034" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4751740" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Corticosteroid therapy in severe alcoholic hepatitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18336666" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of severe forms of alcoholic hepatitis: where are we going?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of acute alcoholic hepatitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964410" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531090" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A randomized trial of prednisolone in patients with severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2648927" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845609" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26870933" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Therapeutic Strategies for the Treatment of Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821406" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pentoxifylline for alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23489011" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026598" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388710" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026596" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of severe alcoholic hepatitis with corticosteroids and pentoxifylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113085" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19340904" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20480532" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164508" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25611961" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540078" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Update on Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32089834" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recent advances in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070475" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935272" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15046213" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18848937" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663232" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155081" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122768" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054157" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Anabolic-androgenic steroids for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24393837" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Liver transplantation for alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29409981" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24291238" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26710309" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30998988" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24115392" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070476" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Early liver transplantation for severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27280501" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123780" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Substance abuse treatment and its association with relapse to alcohol use after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14672612" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A randomized placebo controlled trial of vitamin E for alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954208" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function&lt;32.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556041" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21085006" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22544466" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Comparison of Maddrey Discriminant Function, Child-Pugh Score and Glasgow Alcoholic Hepatitis Score in predicting 28-day mortality on admission in patients with acute hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6142856" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055548" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Invasive aspergillosis in patients with severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25761863" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23879720" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Determinants of long-term outcome in severe alcoholic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4639358" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Natural history of alcoholic hepatitis. 3. Histological changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3598164" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31042580" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
